Last reviewed · How we verify

Pelvic inflammatory disease due to Mycoplasma hominis — Treatment Landscape & Competitive Intelligence

Pelvic inflammatory disease due to Mycoplasma hominis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pelvic inflammatory disease due to Mycoplasma hominis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Zithromax azithromycin Pfizer Inc. Macrolide antibiotic (azalide) Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor 1991-11-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer Inc. · 1 drug in Pelvic inflammatory disease due to Mycoplasma hominis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pelvic inflammatory disease due to Mycoplasma hominis:

Cite this brief

Drug Landscape (2026). Pelvic inflammatory disease due to Mycoplasma hominis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pelvic-inflammatory-disease-due-to-mycoplasma-hominis. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing